Upgrade your vision and change your life with EVO ICL
Upgrade your vision and change your life with EVO ICL
What Is EVO ICL?
EVO ICL is an implantable lens that corrects nearsightedness, with and without astigmatism, through a minimally invasive procedure. The EVO ICL lens is implanted between your iris (the colored part of the eye) and your natural crystalline lens in a quick and safe 20–30 minute procedure. It’s biocompatible and does not remove corneal tissue, so it works with your natural eye and the lens implant is reversible.
EVO ICL does not cause dry eye syndrome and achieves clear vision both day and night.²⁻⁶ EVO ICL is FDA approved.
How we Compare to Other Vision Correction Procedures
EVO
LASIK
PRK
Safety Features
Reversible lens implant
Flexibility for future procedures
Treats eyes with thin corneas⁹
UV Protection
Long term history
Vision Quality
Sharp and Clear Vision²'³
Patient Experience
20-30 Minute Outpatient Procedure
No Corneal Tissue Removed
Does Not Cause Dry Eye Syndrome⁵'⁶
Lasik and PRK may cause Dry Eye Syndrome⁷'⁸
UV: ultraviolet.
* There is a limit flexibility if future procedures involve the cornea.
** Not applicable
*** Limited
Am I a Potential Good Candidate for EVO ICL?
EVO ICL Candidates:
- Are between 21 and 45 years old.
- Are nearsighted with moderate to severe myopia (-3D to -20D).
- Have not had a change in prescription of more than 0.5D in a year.
- Are looking for a procedure that doesn’t cause dry eye syndrome.
Quick Procedure, Quick Recovery, Great Eyesight
Real Life Stories From Real Life Patients
These patients have ICL lenses and were sponsored by STAAR Surgical.
Find a doctor in your area.
Select Your Region
Latin America
References
1. Packer M. The Implantable Collamer Lens with a central port: review of the literature. Clin Ophthalmol. 2018;12:2427-2438.
2. Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125.
3. Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clinical Ophthalmology. 2022;16:1541-53.
4. Parkhurst GD. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clin Ophthalmol. 2016;10:1209-1215.
5. Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-1263.
6. Naves J.S, Carracedo G, Cacho-Babillo I, Diadenosine nucleotid measurements as dry-eye score in patients after LASIK and ICL surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012.
7. Shoja, MR. Besharati, MR. Dry eye after LASIK for myopia: Incidence and risk factors. European Journal of Ophthalmology. 2007; 17(1): pp. 1-6.
8. Lee, Jae Bum et al. Comparison of tear secretion and tear film instability after photorefractive keratectomy and laser in situ keratomileusis. Journal of Cataract & Refractive Surgery , Volume 26 , Issue 9 , 1326 - 1331.
9. Parkhurst, G. Psolka, M. Kezirian, G. Phakic intraocular lens implantantion in United States military warfighters: A retrospective analysis of early clinical outcomes of the Visian ICL. J Refract Surg. 2011;27(7):473-481.
Feeling unsure?
We get it. Decisions like this take time to consider and research. We can help guide your decision with information that's the most relevant to you.
Do you currently wear glasses or contacts?